UBS raises Teva price target - Globes
Generic Drug Lawsuit Could Mean Big Fines for Teva, Mylan: UBS
Investors question green tint of Teva's $5bn sustainability bond | Financial Times
Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets
Teva Pharmaceuticals is found liable in the opioid crisis : NPR
Suffering from missteps, drugmaker Teva struggles to heal own ills | The Times of Israel
Teva jumps after Wall Street upgrades, analysts say stock 'too cheap to ignore'
Summer of Teva: The Mom Comfort Sandal
Teva boosted as FDA delays generic Copaxone - Globes
Teva says vaccine makers have not taken its offer to help produce jabs | Financial Times
Teva Pharmaceuticals Archives - Drug Discovery and Development
Quest upgraded while Teva downgraded at UBS, and VectiveBio scores two new buy initiations in today's analyst action - ADVFN
Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement - MarketWatch
UBS cuts estimate of Teva's opioid liability - Globes
Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement - MarketWatch
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Teva Pharmaceuticals Could Face Billions in Damages From Opioid Lawsuits | Barron's
$4.4 Billion Opioid Settlement Gives Teva Stock a Boost | Barron's
Teva stock drops on guidance, manufacturing problems - MarketWatch
Teva Prepared to Fight Charges in Generics Probe If Talks Fail - Bloomberg
Teva cut to Sell at UBS citing uncertainty over leadership transition (NYSE: TEVA) | Seeking Alpha
Teva in Talks to Buy Allergan's Generic-Drug Unit - WSJ
Brussels' Teva probe reveals dark side of patent protections | Financial Times
Teva Tries to Put an End to the Opioid Wars - WSJ
